Since 1963, Fidia has pioneered the clinical application of hyaluronic acid and has paved the way to a new concept and a novel medical approach: Regenerative Medicine.
After decades of cutting-edge research and a solid scientific and clinical evidence (over 250 international studies published by Fidia), hyaluronic acid has earned globally recognized accreditation as a cornerstone in the stimulation of the natural repair and regeneration processes of damaged tissues, as a result of pathological events, aging or trauma.
Today, Regenerative Medicine, more specifically Autologous Biological Therapy, offers a promising new synergic role for hyaluronic acid, thanks to the development of new therapeutic strategies in all areas where Fidia is already present, thereby enabling the company to always be a step ahead and establish new standards in medical treatment for: Musculoskeletal Care, Advanced Wound Care, Aesthetic Medicine, Ophthalmology.
A comprehensive medical device portfolio for obtaining autologous biological products at the point-of-care, with high quality, safety and efficacy profile, that allow physicians to customize the best science-based regenerative therapies to the individual patients.
BY BIOLOGICAL CONTEXT